Eiry Roberts - 13 Feb 2023 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Medical Officer
Issuer ticker: NBIX
Reported as of: 13 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Feb 2023, 18:15:54 UTC
Prior SEC filing: 08 Feb 2023
Next SEC filing: 26 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Eiry Roberts filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 15 Feb 2023.

Key facts

This page summarizes Eiry Roberts's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 15 Feb 2023, 18:15.

Change

Previous filing in this sequence was filed on 08 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBIX transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +52,532
Change %
Price: $0.000000
Shares after: 52,532
Date: 13 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 52,532
Exercise price: $103.52
Footnotes: F1

NBIX transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +8,453
Change %
Price: $0.000000
Shares after: 8,453
Date: 13 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,453
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Footnote F2

Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

Footnote F3

The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027.